Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/890"
| Predicate | Value (sorted: none) |
|---|---|
| rdf:type | |
| rdf:type | |
| rdfs:label | |
| ?:Evidence_type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_value | |
| dc:creator | |
| dc:date |
"02/09/2012 12:01:55"
|
| ?:content |
"NOTE: The object dose given is for days 6-11 of the study. The AUC_i/AUC was calculated from Table 1.
route of administration: oral (indinavir)
study duration: 11 days
population: 8 healthy subjects (5 male, 3 female)
tested for known CYP450 polymorphisms?
YES - CYP2D6 phenotyping -- one poor metabolizer
ages: over 18
description:
SUBJECTS: Nine subjects entered the study and were phenotyped and 8 of the 9 subjects completed the study (5 males, 3 females). One CYP2D6 poor metabolizer (PM) was identified and inclusion of her data had no effect on the outcome of the analyses.
METHODS: The protocol was conducted in three phases: indinavir administered alone (I), venlafaxine administered alone (II), and indinavir administered after achieving expected steady-state plasma concentrations of venlafaxine (III). During phase I, subjects received one 800 mg dose of indinavir on an empty subject. Phase II of the study began the following day with subjects taking venlafaxine according to the following titration schedule: 25 mg every 8 hours for 4 days increased to 50 mg every 8 hours for an additional 4 days. Phase III began on day 11 with each subject simultaneously receiving the morning dose of venlafaxine 50mg and indinavir 800 mg.
RESULTS: The mean AUC of venlafaxine after the addition of a single dose of indinavir demonstrated a nonsignificant increase. Half of the subjects experienced an increased AUC (mean of 55 [27%]) and the other half a decreased AUC (mean of 19 [6%])."
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ indinavir_increases_auc_venlafaxine, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1966 }